TORCH and other perinatal infections: anatomy, timing and action
Compare congenital infection patterns, interpret maternal and infant tests, and choose timely prevention and treatment for TORCH and related pathogens.
A newborn with hearing loss does not have a diagnosis yet. The eye structure affected, the distribution of brain injury and the timing of maternal exposure can separate several congenital infections. The next test must also distinguish infection acquired before birth from maternal antibodies or infection acquired afterward.
Use three clocks: maternal exposure, fetal injury and the diagnostic window
TORCH is a memory aid for toxoplasmosis, other infections, rubella, cytomegalovirus and herpes. The “other” category is essential: syphilis, varicella, parvovirus B19 and HIV do not become less important because they share one letter. Some cause a recognizable malformation pattern; others mainly cause neonatal sepsis, anemia or later hearing loss. A single universal TORCH panel cannot answer all of these different questions.
During pregnancy
Ask when infection occurred and whether fetal transmission or injury is established. Earlier injury can be more severe even when transmission is less frequent.
At delivery
Maternal infection activity and treatment determine exposure risk. HSV, HIV and peripartum varicella require delivery-specific decisions.
After birth
Collect pathogen-appropriate specimens on time. A CMV result obtained too late may not establish congenital infection. Some sequelae emerge after a normal newborn examination.
The three clocks answer different questions: exposure timing, clinical injury and test interpretation. They should be recorded separately.
Maternal IgG crosses the placenta. A positive neonatal IgG result can therefore reflect passive antibody rather than infant infection. IgM does not normally cross, but infant IgM can be absent despite infection, and maternal IgM may persist or be falsely positive. Antibody class is a starting principle, not a complete diagnostic algorithm. Use each pathogen's validated tests, specimen timing and maternal history. [4][6][7][18]
Routine prenatal prevention includes indicated HIV, hepatitis B, hepatitis C and syphilis screening, rubella immunity assessment and other tests based on clinical context. ACOG now recommends syphilis testing at the first prenatal visit, in the third trimester and at birth. GBS culture is collected at 36 weeks 0 days through 37 weeks 6 days in the routine pathway. These are specific screening programs, not a blanket request for every TORCH IgM. [6][23][20][21]
Growth restriction, hepatosplenomegaly, jaundice and petechiae overlap across infections. A blue-purple “blueberry muffin” eruption is also not exclusive to one pathogen; dermal blood-cell production and other processes can create overlapping appearances. Use these findings to trigger evaluation, then seek the more discriminating anatomy and laboratory evidence. [22]
CMV and toxoplasmosis: compare the brain, then verify the infection
Congenital CMV is a leading cause of infection-related sensorineural hearing loss. Microcephaly, petechiae, hepatosplenomegaly and periventricular calcifications form a useful pattern, but many infected newborns have no obvious findings. Infection can follow maternal primary infection, reinfection or reactivation. An asymptomatic mother or preexisting CMV antibody does not rule out fetal infection. [1]
CMV-weighted pattern
Microcephaly, calcifications concentrated near the ventricles, hearing loss and systemic neonatal findings.
Toxoplasma-weighted pattern
Hydrocephalus, more diffusely distributed intracranial calcifications and chorioretinitis.
The comparison changes probability; imaging patterns can overlap and neither is pathognomonic. Congenital toxoplasmosis should not be taught as the same imaging problem as ring-enhancing lesions from reactivated toxoplasmosis in a severely immunocompromised adult. In the eye, chorioretinitis involves the retina and underlying choroid, whereas a cataract clouds the lens. Those are different anatomical lesions. [4][22]
To establish congenital CMV, obtain virologic testing within the first 21 days. Saliva PCR is useful for screening, with a positive result confirmed using urine because contamination can affect saliva results. Antibody tests do not establish congenital CMV. A positive urine PCR at two months, without an early specimen, cannot reliably distinguish congenital from postnatally acquired infection. [1]
Infants with significant symptomatic congenital CMV, particularly central nervous system disease, may benefit from antiviral treatment under specialist guidance. The randomized six-month versus six-week valganciclovir trial did not improve the primary best-ear hearing outcome at six months, but found modest longer-term hearing and developmental advantages. Do not generalize that trial to every asymptomatic infant. Benefit for isolated hearing loss is less certain and deserves specialist discussion. Monitor for marrow toxicity and other drug-related effects during treatment. Valganciclovir is an oral prodrug of ganciclovir. In CMV-infected cells, UL97 performs its initial phosphorylation; the active triphosphate inhibits viral DNA synthesis. Acyclovir depends strongly on HSV/VZV thymidine kinase for initial activation and is not an interchangeable treatment for congenital CMV. [26][27][2]
Toxoplasma exposure can follow undercooked meat containing tissue cysts or ingestion of environmentally acquired oocysts from contaminated soil, water or cat feces. Ordinary contact with a cat is not itself the mechanism. Maternal infection newly acquired during pregnancy is the usual setting for congenital disease. Transmission tends to increase later in gestation, while earlier fetal infection is often more damaging. Rare exceptional transmission circumstances mean prior infection is not an absolute guarantee in every host. [4][22]
Maternal IgM alone cannot reliably date toxoplasmosis. Confirmatory reference-laboratory serology, serial results and appropriately timed amniotic-fluid PCR, generally from 18 weeks with specialist attention to the interval since infection, may be needed. Infant IgM or IgA negativity does not exclude congenital infection. Treatment depends on whether the problem is maternal infection without demonstrated fetal involvement or established fetal/neonatal infection. Spiramycin may be used for early maternal infection when fetal infection is not suspected; pyrimethamine, sulfadiazine and leucovorin are used in other indicated fetal or infant settings. Congenitally infected infants are generally treated for 12 months with specialist monitoring. Leucovorin reduces folate-related marrow toxicity and is an essential part of the regimen. [3][4]
Eye anatomy and timing separate rubella from syphilis
Rubella virus is currently classified in the Matonaviridae family. Congenital rubella classically combines hearing impairment, cataracts and heart disease, especially patent ductus arteriosus or branch pulmonary artery stenosis. Early-pregnancy infection has the greatest risk of major congenital injury. A cataract is a lens abnormality, so do not substitute it for the retinal inflammation emphasized in toxoplasmosis. Rubella can also cause other eye findings and systemic signs; the classic triad is not required in full. No specific antiviral treatment is established; care addresses the infant's cardiac, hearing, eye and developmental needs. [25][5]
Assess rubella immunity with IgG. Routine IgM screening of an asymptomatic, unexposed pregnant patient creates avoidable false-positive problems. A positive unexpected IgM needs confirmation and clinical interpretation, potentially including expert avidity assessment. Neonatal IgM and pathogen detection can support congenital rubella diagnosis; persistent infant IgG after maternal antibody should have waned is another diagnostic route. Maternal IgM alone does not prove fetal infection. [6]
MMR is a live vaccine and is not given during pregnancy. Vaccinate susceptible patients postpartum and advise avoiding conception for 28 days after MMR. Inadvertent vaccination during an unrecognized pregnancy is not, by itself, an indication for pregnancy termination. The theoretical vaccine concern must not be presented as equivalent to the known risk from wild-type rubella infection. [19]
Treponema pallidum can cross the placenta; there is no safe early-gestation interval established by a rigid “after 16 weeks” rule. Early congenital syphilis may cause snuffles, a palm-and-sole rash, hepatosplenomegaly, jaundice, bone inflammation and painful pseudoparalysis. Moist lesions such as condylomata lata can occur as well. Later findings include Hutchinson teeth, interstitial keratitis, sensorineural deafness, saddle-nose deformity, saber shins and painless joint swelling. Interstitial keratitis affects corneal tissue, a third eye location distinct from lens cataract or chorioretinitis. [7][8][22]
Interpret maternal and neonatal testing together. Use the infant's serum, not cord blood, and compare quantitative nontreponemal results using the same test as the mother. An infant titer at least fourfold higher supports highly probable infection, but a smaller difference does not exclude congenital syphilis. Examination, adequacy and timing of maternal treatment, reinfection risk and neonatal evaluation all enter the decision. Selected evaluations include cerebrospinal fluid studies, blood count and long-bone radiographs. Infants with reactive nontreponemal tests require clinical and serologic follow-up, generally every two to three months until the test becomes nonreactive. [7]
Symptomatic or highly probable neonatal disease requires a full recommended penicillin course, generally 10 days. If more than one day is missed in the neonatal 10-day regimen, restart the course. Lower-risk scenarios have different pathways and should not be collapsed into “every exposed baby receives identical intravenous treatment.” For maternal syphilis, stage-appropriate penicillin is the proven treatment to prevent congenital infection; a true allergy requires desensitization rather than substituting an inadequately supported fetal-protection regimen. [7][8]
HSV and varicella: distinguish established disease from exposure prevention
Most neonatal HSV is acquired around delivery; rare intrauterine or postnatal acquisition also occurs. Both HSV-1 and HSV-2 can cause serious neonatal disease. Classify illness as skin-eye-mouth disease, central nervous system disease or disseminated disease. A septic-appearing infant with hepatitis or seizures may have no vesicles. Absence of a maternal herpes history also does not exclude neonatal HSV. [9]
Evaluate suspected neonatal HSV promptly and give systemic intravenous acyclovir while appropriate virologic and bacterial studies are pursued. Skin-eye-mouth disease still requires systemic treatment. CDC lists 20 mg/kg every eight hours for 14 days for disease limited to skin and mucous membranes, and 21 days for central nervous system or disseminated disease, with dosing adjusted for renal function and neonatal circumstances. Initial negative testing does not justify ignoring a strongly suspicious evolving illness; specialist assessment may require repeat cerebrospinal fluid testing. After acute therapy, arrange follow-up and indicated oral acyclovir suppression; survivors of CNS disease generally receive six months of suppression. [24][9]
For recurrent maternal genital herpes, suppressive treatment beginning at 36 weeks reduces recurrences at term. At labor, active lesions or prodromal symptoms support cesarean delivery to reduce exposure. A remote history without current findings is not an automatic cesarean indication. Cesarean reduces risk but cannot be promised to eliminate every neonatal infection.
Varicella requires two different timelines. Rare congenital varicella after infection early in pregnancy may cause dermatomal scars, limb hypoplasia and eye or neurologic abnormalities. Maternal rash from five days before through two days after delivery creates a particularly dangerous neonatal exposure because protective antibody transfer may be inadequate. The neonatal exposure problem is not the same as an established congenital malformation syndrome. [10]
Eligible high-risk exposed patients receive varicella-zoster immune globulin as soon as possible, within ten days of exposure. An old 96-hour cutoff should not be used to deny indicated VariZIG on day five. Immune globulin is prevention after exposure; intravenous acyclovir treats indicated severe or neonatal disease. Not every asymptomatic exposed infant automatically receives the same treatment as an infant with disseminated varicella. [10][11]
Parvovirus B19: follow the consequence of failed erythropoiesis
Parvovirus B19 targets erythroid precursor cells. Binding to the P antigen is part of its cell interaction, but receptor expression alone does not explain all tissue permissiveness. Suppression of fetal erythropoiesis can produce profound anemia, high-output cardiac failure and hydrops. Maternal illness may be mild, with rash or joint symptoms, while fetal effects are serious. [12][14]
Hydrops means abnormal fluid in at least two fetal compartments, such as ascites, pleural fluid, pericardial fluid or skin edema. It describes a physiologic state, not an organism. Alloimmune anemia, structural heart disease, arrhythmia, genetic disease and other infections remain alternatives. The number of fluid compartments cannot exclude a cardiac cause. A negative maternal red-cell antibody screen helps assess alloimmunization but does not identify parvovirus by itself.
Following a meaningful exposure or compatible illness, use maternal serology and specialist-directed fetal surveillance. Routine universal parvovirus screening is not the same as exposure-directed testing. Middle cerebral artery peak systolic velocity is used to assess risk for fetal anemia. A value above 1.5 multiples of the median or hydrops warrants urgent fetal-medicine evaluation for fetal blood sampling with preparation for possible intrauterine transfusion, balanced against gestational age and delivery risks. The Doppler value is not an instruction to transfuse blindly. [12][13]
Prevent HIV transmission with viral-load-based decisions
Effective maternal antiretroviral therapy is central throughout pregnancy. Near delivery, HIV RNA and treatment history guide intrapartum zidovudine and delivery planning. When HIV RNA exceeds 1,000 copies/mL or is unknown near delivery, scheduled cesarean at 38 weeks is generally recommended before labor, with indicated intrapartum medication. Suppressed viral load does not require cesarean solely for HIV prevention. If labor or membrane rupture has already occurred, management requires an individualized assessment. [15]
Start neonatal prophylaxis or presumptive therapy promptly according to exposure risk. In the defined low-risk situation of sustained maternal HIV RNA below 50 copies/mL from 20 weeks through delivery, a nonbreastfed infant generally receives two weeks of zidovudine. Higher-risk exposure may require a multidrug presumptive regimen. The chosen drugs, duration and testing depend on current guidance, gestational age and the actual maternal course. [16]
Use HIV nucleic acid testing in young exposed infants rather than interpreting transferred maternal antibody as proof of infection. The schedule includes testing at 14 to 21 days, one to two months and four to six months, with birth and additional testing determined by risk, therapy and breastfeeding. Do not delay prophylaxis while waiting for a specimen result. [18]
Discuss feeding using current evidence and shared decision-making. Properly prepared formula or pasteurized donor human milk eliminates postnatal HIV transmission through breast milk. Sustained viral suppression with therapy makes breastfeeding transmission risk less than 1%, but not zero; breastfeeding plans require coordinated maternal and infant monitoring. An absolute prohibition for every suppressed patient and a promise of zero risk are both inaccurate. [17]
Prevention also includes safer food handling and soil precautions for toxoplasmosis, hand hygiene around young children's saliva and urine for CMV, and appropriate vaccination. Inactivated or recombinant influenza vaccine may be given during pregnancy; Tdap is recommended during each pregnancy, preferably early in the 27-to-36-week window. MMR and varicella vaccination are planned outside pregnancy. Review current respiratory-virus vaccine guidance during prenatal care rather than treating an old product schedule as permanent. [4][1][19]
Cases: choose the test, treatment or prevention decision
Each original scenario supplies the timing needed to distinguish maternal exposure, fetal injury and neonatal disease.
Case 1
Show answer and explanations for case 1
A. Toxoplasmosis (Why this does not fit)
Hydrocephalus and more diffuse calcifications would favor toxoplasmosis, although imaging overlap prevents certainty without testing.
B. Rubella (Why this does not fit)
Cataracts and characteristic cardiac lesions would strengthen rubella over this brain-weighted pattern.
C. Syphilis (Why this does not fit)
Snuffles, palm-and-sole rash and bone findings would be more characteristic discriminators.
D. Cytomegalovirus (Best answer)
The periventricular distribution, hearing loss and systemic newborn findings favor CMV.
Takeaway: An anatomical pattern guides testing; it is not a substitute for confirmation.
A. Maternal therapy can stop once breastfeeding begins (Why this does not fit)
Continued suppression is central to reducing transmission risk.
B. Discuss feeding choices: replacement feeding eliminates milk transmission, while suppression makes breastfeeding risk very low but not zero (Best answer)
Shared decision-making includes the residual risk and coordinated follow-up if breastfeeding is chosen.
C. Undetectable viral load guarantees zero breastfeeding transmission risk (Why this does not fit)
The evidence does not justify a zero-risk guarantee for breastfeeding.
D. Every suppressed patient must be denied discussion of breastfeeding (Why this does not fit)
Current guidance supports informed shared decision-making.
Takeaway: Respect feeding decisions while stating the actual evidence and monitoring requirements.
